Lytix Biopharma AS will release its second quarter 2023 results on Thursday,
August 31. The results will be presented in a webcast with CEO Øystein Rekdal,
CDO Graeme Currie and CFO Gjest Breistein at 2:30 pm CEST. 

The presentation and subsequent Q&A session will be held in English and may be
viewed live by registering here: https://forms.office.com/e/FPEmPcUjX1

The results report and the presentation will be available at
www.lytixbiopharma.com in the Investors section from 08:00 am CET, and a
recording of the presentation will after the presentation be made available.

***

For more information, please contact: 
* Gjest Breistein, CFO: gjest.breistein@lytixbiopharma.com
* Ole Peter Nordby, Head of IR & Communication Manager:
ole.peter.nordby@lytixbiopharma.com


Lytix in brief: 
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immuno-oncology
company developing novel cancer immunotherapies, an area within cancer therapy
that is aimed at activating the patient's immune system to fight cancer. The
Company's technology is based on pioneering research in "host defense peptides"
- nature's first line of defense towards foreign pathogens. Lytix Biopharma's
lead product, LTX-315, is a first-in-class molecule representing a new and
superior therapeutic principle to kill cancer cells and boost anti-cancer
immunity, with the potential to be the ideal combination partner with other
types of immunotherapy. LTX-315 target cancer cells and disintegrate their cell
membranes, causing immunogenic cell death and release of a patient's tumor
specific antigens.  This mode of action allows cytotoxic T cells to recognize,
infiltrate, and attack cancer cells. The Company was listed on Euronext Growth
in Oslo in June 2021, following a private placement covered by investors such as
PBM Capital, a US based, healthcare-focused investment firm.